Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
NA
Total Enrollment
268 participants
Study Classification
INTERVENTIONAL
Study Start Date
2011-02-28
Study Completion Date
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study seeks to determine the rate of thromboembolic complications (blood clots), including death attributed to thromboembolic disease, when anticoagulation (blood thinner) therapy is withheld from pregnant patients suspected of deep vein thrombosis (DVT) after a whole-leg compression ultrasound shows no DVT. Patients are followed for three months after the ultrasound to determine if a blood clot is diagnosed during that time.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Assessment of the Deep Vein Thrombosis (DVT) in Hospitalized Obstetrics Patients
NCT02697123
Venous Thrombosis
Pregnancy
TERMINATED
Single Complete Compression Ultrasonography to Rule Out Deep Vein Thrombosis During Pregnancy and Postpartum
NCT00740454
Deep Vein Thrombosis
COMPLETED
Simplification of the Diagnosis of Deep Vein Thrombosis
NCT01412242
Deep Venous Thrombosis
COMPLETED
PHASE3
Ultrasound Assessment of Isolated Distal Deep Vein Thrombosis
NCT06596941
Iddvt
Pulmonary Embolism (PE)
ACTIVE_NOT_RECRUITING
Limited Compression Ultrasound by Emergency Physicians to Exclude Deep Vein Thrombosis
NCT01007045
Deep Vein Thrombosis
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
SPECIFIC AIM To determine the rate of thromboembolic complications (including death attributed to thromboembolic disease) in pregnant patients suspected of deep vein thrombosis (DVT) when anticoagulation therapy is withheld on the basis of a negative whole-leg compression ultrasound examination (whole-leg CUS).
BACKGROUND AND SIGNIFICANCE
The diagnosis of deep vein thrombosis of the leg is challenging due to the great variability of clinical presentation and the lack of sensitivity of noninvasive tests. This is particularly true for pregnant patients, who have been excluded from most major studies of diagnostic strategies for DVT. Ironically, pregnancy is considered a major risk factor for DVT, making evidence-based diagnosis in this patient group particularly important.
A study performed at LDS Hospital, found that a single, whole-leg compression ultrasound could safely exclude the diagnosis of suspected, symptomatic, first-episode deep vein thrombosis of the leg. A subsequent metanalysis of studies of the same technique confirmed this finding, but observed that the utility of this strategy in pregnant patients required further study, as only 57 of the over 4,500 subjects in the pooled metanalysis were pregnant.
Therefore, better information regarding the performance of diagnostic testing for suspected DVT in pregnant patients is needed. If whole-leg compression ultrasound proves adequately sensitive in this patient group, this will be a significant step in simplifying the diagnostic process for deep vein thrombosis, and will confirm the diagnostic strategy most commonly used presently by physicians at Intermountain Medical Center.
EXPERIMENTAL DESIGN AND METHODS
Design Prospective clinical cohort study ("management study").
Patients 268 sequentially-enrolled pregnant patients evaluated for suspected symptomatic deep vein thrombosis of the leg, reporting to the Intermountain Medical Center Peripheral Vascular Laboratory. Vascular technicians will pre-screen patients for study entry with a simple questionnaire. Those meeting screening criteria will then be interviewed by the study coordinator to verify they meet inclusion criteria, have no reason for exclusion, and provide informed consent.
Demographic and medical history information:
Clinical information relevant to the study will be obtained from the Study Coordinator following informed consent during the initial study interview. Query of the Intermountain Healthcare electronic medical record will also be performed at entry. Relevant information will be included on a standardized Case Report Form.
Informed Consent documents, Case Report Forms and relevant source documents from the electronic medical record will be obtained, placed in a study binder and stored according to the policies of the Institutional Review Board.
Measurements:
A research clinician will perform a brief clinical assessment, including adequate information to calculate the LeFT clinical prediction score, which has been evaluated in a prior study. Patients will then proceed to performance of whole-leg compression ultrasound.
Objective Testing for Venous Thrombosis Whole-leg CUS will be performed on all patients. A standardized technique will be used for the CDU examination, which is identical to the protocol used clinically by the Intermountain Medical Center Peripheral Vascular Laboratory.
Compressibility of the veins will be assessed. The results will be categorized as normal if all imaged venous segments are fully compressible, as abnormal if a noncompressible segment is identified, or as inadequate for interpretation.
If the vascular technologist develops suspicion of isolated iliac DVT (based on absence of phasic respiratory flow or complete absence of flow in the common femoral vein by Doppler, but with normal compression) the referring physician and principal investigator will be contacted immediately by telephone. Further evaluation (usually by an alternate imaging modality) will be ordered at the discretion of the referring physician according to best clinical judgment.
Interpretation will be performed by experienced vascular surgery staff according to protocols currently in use at Intermountain Medical Center. Findings will be redacted to specific data fields by the interpreting surgeon according to a form generated for this purpose, and entered onto a Case Report Form.
Interobserver variability will be limited by using a priori criteria for a positive and negative study. Interobserver agreement for this technique has been found to be high in a prior study.
If the result of initial whole-leg CUS is normal (no DVT identified), anticoagulation will be withheld, regardless of symptoms.
If the result of testing is abnormal (DVT identified), the patient will be referred to the treating clinician for usual management at the discretion of the clinician. This group will not be followed for study outcomes.
Subjects whose results are classified as inadequate for interpretation will have reasons logged and be excluded from analysis. They will receive further management according to the discretion of the treating physician.
Long-Term Follow-up Patients with a negative whole-leg CUS will undergo three months of clinical follow-up, a strategy used in many diagnostic trials for DVT.2 Patients will be instructed to return immediately to our emergency department if they have symptoms or signs of DVT or pulmonary embolism (PE). A study clinician will assess them at 3 months by telephone interview using a standardized questionnaire.
If patients contact the study team with symptoms suspicious for DVT or PE, they will be evaluated by a study clinician in the Thrombosis Clinic (symptoms of DVT), or referred to emergent care for evaluation (symptoms of PE). Participants' treating clinicians are also free to obtain any medically appropriate diagnostic testing for suspected DVT or PE during the follow-up period. A letter will be sent to referring physicians explaining the protocol and emphasizing that any appropriate diagnostic testing for suspected DVT or PE may be performed as clinically indicated.
At the follow-up assessment, an interval history will be taken with emphasis on specific symptoms (including leg pain, tenderness and swelling, chest pain, dyspnea, hemoptysis, and syncope), hospitalization, interval evaluation for DVT or PE and use of anticoagulants. For all patients who die, the cause of death will be determined from autopsy or by independent clinical review if autopsy cannot be obtained. If at follow-up a patient identifies symptoms suspicious for DVT or PE that have not previously been clinically evaluated, they will be scheduled for an in-person evaluation with a physician in the Intermountain Medical Center Thrombosis Clinic.
In addition to information obtained from the patient during the follow-up visit, a comprehensive review of the patient's Intermountain electronic health record will be performed to look for evidence of diagnostic testing for deep vein thrombosis or pulmonary embolism or use of anticoagulant medications. Additionally, the study coordinator presently receives alerts of all positive diagnostic tests for DVT and PE performed in the facility daily. This list will be reviewed for study participants.
Results of the follow-up assessment will be entered on a Case Report Form by study staff. This form will be added to the study binder by the study coordinator and information appended to the database by the data entry clerk.
The study will be designed to estimate the event rate of thromboembolic disease and death attributable to thromboembolic disease in the normal cohort during the three-month follow-up period. An exact 95% confidence interval that excludes a rate of VTE of 3% or greater will be defined as clinically acceptable, in accordance with previous trials of DVT diagnosis.
The study will report analysis of outcomes both on a per-protocol and intention-to-treat basis in the event of protocol violation (i.e. receipt of therapeutic anticoagulation despite negative whole-leg ultrasound, without objective evidence of a thrombotic complication).
In the event of withdrawal of participation, affected subjects will be suppressed from analysis (i.e. analysis will be performed on a per protocol basis), or in the event that isolated iliac DVT is diagnosed following vascular technologist suspicion. Isolated iliac DVT diagnosed after additional imaging resulting from technologist suspicion will be analyzed as an additional outcome variable, and the rate of this diagnosis reported with a corresponding exact 95% confidence interval. Use of intention-to-treat analysis could bias results of the study in the case of withdrawn subjects as they would, by definition, not complete the defined follow-up period and would not have ascertainment of the primary study outcome.
Adjudication of Outcomes A panel of three independent physicians with established expertise in venous thromboembolism will be named to adjudicate all suspected events of DVT or PE, and all diagnostic tests for these occurring during the follow-up period. Simple majority will resolve disputes. All deaths will be adjudicated as to whether attributable to PE or another cause by the same group of adjudicators.
Methodological Issues and Avoidance of Bias Entering consecutive patients into the study will avoid selection bias. To avoid bias during the initial testing period, we have established pre-defined criteria for negative and positive studies. Further diagnostic testing on patients with negative results will not be undertaken unless dictated by new or progressive symptoms. Patients with a negative whole-leg CUS will not be treated and therapy will be given to all patients with positive results.
Diagnostic suspicion bias will be avoided by objectively testing all patients who return during follow-up with symptoms or signs suggestive of deep venous thrombosis or pulmonary embolism. Interpretation bias will be avoided by obtaining independent interpretation of follow-up testing in patients with suspected disease by independent adjudicators. The adjudicators will be blinded to the results of the initial ultrasound and the cohort to which the patient belongs. All deaths will be independently reviewed. The adjudicators will be blinded to the cohort to which the patient belongs.
Patient confidentiality will be maintained by keeping the patient identity log separate from the database, which will use only unique numerical identifiers. Complete data tracking will be assured by comparison of enrollment log and database by independent reviewer.
STATISTICAL ANALYSIS
Descriptive statistics for age, weight, height, trimester (weeks gestation), symptoms at presentation (pain, tenderness, duration of symptoms), clinical conditions (recent surgery, recent hospitalization, cancer, congestive heart failure, recent immobilization, cellulitis, superficial phlebitis and family history of thromboembolic disease) and the LeFT variables (including leg circumference) will be calculated to characterize the study population.
The event rate of thromboembolic complications and death from thromboembolic disease will be calculated for patients with negative whole-leg CUS; both per-protocol and by intention-to-treat.
The rate of isolated iliac DVT detected after vascular technologist suspicion will be reported as a separate calculation with corresponding exct 95% confidence interval
A two-sided confidence interval for the event rate (objectively verified venous thromboembolism) will be calculated for the observation cohort by exact methods. If this confidence interval excludes the commonly accepted threshold event rate of 3%, we will conclude that the diagnostic strategy is clinically valid.
We will also describe the clinical characteristics of clots (e.g. venous distribution) and other endpoints when those data are available.
The sample size of 268 patients who meet eligibility criteria was chosen so that an exact 95% confidence interval would exclude an event rate of venous thromboembolism in the observation cohort of 3%. Excluding an event rate of 3% is the commonly accepted standard by which diagnostic strategies are deemed clinically acceptable.
BACKGROUND AND SIGNIFICANCE
The diagnosis of deep vein thrombosis of the leg is challenging due to the great variability of clinical presentation and the lack of sensitivity of noninvasive tests. This is particularly true for pregnant patients, who have been excluded from most major studies of diagnostic strategies for DVT. Ironically, pregnancy is considered a major risk factor for DVT, making evidence-based diagnosis in this patient group particularly important.
A study performed at LDS Hospital, found that a single, whole-leg compression ultrasound could safely exclude the diagnosis of suspected, symptomatic, first-episode deep vein thrombosis of the leg. A subsequent metanalysis of studies of the same technique confirmed this finding, but observed that the utility of this strategy in pregnant patients required further study, as only 57 of the over 4,500 subjects in the pooled metanalysis were pregnant.
Therefore, better information regarding the performance of diagnostic testing for suspected DVT in pregnant patients is needed. If whole-leg compression ultrasound proves adequately sensitive in this patient group, this will be a significant step in simplifying the diagnostic process for deep vein thrombosis, and will confirm the diagnostic strategy most commonly used presently by physicians at Intermountain Medical Center.
EXPERIMENTAL DESIGN AND METHODS
Design Prospective clinical cohort study ("management study").
Patients 268 sequentially-enrolled pregnant patients evaluated for suspected symptomatic deep vein thrombosis of the leg, reporting to the Intermountain Medical Center Peripheral Vascular Laboratory. Vascular technicians will pre-screen patients for study entry with a simple questionnaire. Those meeting screening criteria will then be interviewed by the study coordinator to verify they meet inclusion criteria, have no reason for exclusion, and provide informed consent.
Demographic and medical history information:
Clinical information relevant to the study will be obtained from the Study Coordinator following informed consent during the initial study interview. Query of the Intermountain Healthcare electronic medical record will also be performed at entry. Relevant information will be included on a standardized Case Report Form.
Informed Consent documents, Case Report Forms and relevant source documents from the electronic medical record will be obtained, placed in a study binder and stored according to the policies of the Institutional Review Board.
Measurements:
A research clinician will perform a brief clinical assessment, including adequate information to calculate the LeFT clinical prediction score, which has been evaluated in a prior study. Patients will then proceed to performance of whole-leg compression ultrasound.
Objective Testing for Venous Thrombosis Whole-leg CUS will be performed on all patients. A standardized technique will be used for the CDU examination, which is identical to the protocol used clinically by the Intermountain Medical Center Peripheral Vascular Laboratory.
Compressibility of the veins will be assessed. The results will be categorized as normal if all imaged venous segments are fully compressible, as abnormal if a noncompressible segment is identified, or as inadequate for interpretation.
If the vascular technologist develops suspicion of isolated iliac DVT (based on absence of phasic respiratory flow or complete absence of flow in the common femoral vein by Doppler, but with normal compression) the referring physician and principal investigator will be contacted immediately by telephone. Further evaluation (usually by an alternate imaging modality) will be ordered at the discretion of the referring physician according to best clinical judgment.
Interpretation will be performed by experienced vascular surgery staff according to protocols currently in use at Intermountain Medical Center. Findings will be redacted to specific data fields by the interpreting surgeon according to a form generated for this purpose, and entered onto a Case Report Form.
Interobserver variability will be limited by using a priori criteria for a positive and negative study. Interobserver agreement for this technique has been found to be high in a prior study.
If the result of initial whole-leg CUS is normal (no DVT identified), anticoagulation will be withheld, regardless of symptoms.
If the result of testing is abnormal (DVT identified), the patient will be referred to the treating clinician for usual management at the discretion of the clinician. This group will not be followed for study outcomes.
Subjects whose results are classified as inadequate for interpretation will have reasons logged and be excluded from analysis. They will receive further management according to the discretion of the treating physician.
Long-Term Follow-up Patients with a negative whole-leg CUS will undergo three months of clinical follow-up, a strategy used in many diagnostic trials for DVT.2 Patients will be instructed to return immediately to our emergency department if they have symptoms or signs of DVT or pulmonary embolism (PE). A study clinician will assess them at 3 months by telephone interview using a standardized questionnaire.
If patients contact the study team with symptoms suspicious for DVT or PE, they will be evaluated by a study clinician in the Thrombosis Clinic (symptoms of DVT), or referred to emergent care for evaluation (symptoms of PE). Participants' treating clinicians are also free to obtain any medically appropriate diagnostic testing for suspected DVT or PE during the follow-up period. A letter will be sent to referring physicians explaining the protocol and emphasizing that any appropriate diagnostic testing for suspected DVT or PE may be performed as clinically indicated.
At the follow-up assessment, an interval history will be taken with emphasis on specific symptoms (including leg pain, tenderness and swelling, chest pain, dyspnea, hemoptysis, and syncope), hospitalization, interval evaluation for DVT or PE and use of anticoagulants. For all patients who die, the cause of death will be determined from autopsy or by independent clinical review if autopsy cannot be obtained. If at follow-up a patient identifies symptoms suspicious for DVT or PE that have not previously been clinically evaluated, they will be scheduled for an in-person evaluation with a physician in the Intermountain Medical Center Thrombosis Clinic.
In addition to information obtained from the patient during the follow-up visit, a comprehensive review of the patient's Intermountain electronic health record will be performed to look for evidence of diagnostic testing for deep vein thrombosis or pulmonary embolism or use of anticoagulant medications. Additionally, the study coordinator presently receives alerts of all positive diagnostic tests for DVT and PE performed in the facility daily. This list will be reviewed for study participants.
Results of the follow-up assessment will be entered on a Case Report Form by study staff. This form will be added to the study binder by the study coordinator and information appended to the database by the data entry clerk.
The study will be designed to estimate the event rate of thromboembolic disease and death attributable to thromboembolic disease in the normal cohort during the three-month follow-up period. An exact 95% confidence interval that excludes a rate of VTE of 3% or greater will be defined as clinically acceptable, in accordance with previous trials of DVT diagnosis.
The study will report analysis of outcomes both on a per-protocol and intention-to-treat basis in the event of protocol violation (i.e. receipt of therapeutic anticoagulation despite negative whole-leg ultrasound, without objective evidence of a thrombotic complication).
In the event of withdrawal of participation, affected subjects will be suppressed from analysis (i.e. analysis will be performed on a per protocol basis), or in the event that isolated iliac DVT is diagnosed following vascular technologist suspicion. Isolated iliac DVT diagnosed after additional imaging resulting from technologist suspicion will be analyzed as an additional outcome variable, and the rate of this diagnosis reported with a corresponding exact 95% confidence interval. Use of intention-to-treat analysis could bias results of the study in the case of withdrawn subjects as they would, by definition, not complete the defined follow-up period and would not have ascertainment of the primary study outcome.
Adjudication of Outcomes A panel of three independent physicians with established expertise in venous thromboembolism will be named to adjudicate all suspected events of DVT or PE, and all diagnostic tests for these occurring during the follow-up period. Simple majority will resolve disputes. All deaths will be adjudicated as to whether attributable to PE or another cause by the same group of adjudicators.
Methodological Issues and Avoidance of Bias Entering consecutive patients into the study will avoid selection bias. To avoid bias during the initial testing period, we have established pre-defined criteria for negative and positive studies. Further diagnostic testing on patients with negative results will not be undertaken unless dictated by new or progressive symptoms. Patients with a negative whole-leg CUS will not be treated and therapy will be given to all patients with positive results.
Diagnostic suspicion bias will be avoided by objectively testing all patients who return during follow-up with symptoms or signs suggestive of deep venous thrombosis or pulmonary embolism. Interpretation bias will be avoided by obtaining independent interpretation of follow-up testing in patients with suspected disease by independent adjudicators. The adjudicators will be blinded to the results of the initial ultrasound and the cohort to which the patient belongs. All deaths will be independently reviewed. The adjudicators will be blinded to the cohort to which the patient belongs.
Patient confidentiality will be maintained by keeping the patient identity log separate from the database, which will use only unique numerical identifiers. Complete data tracking will be assured by comparison of enrollment log and database by independent reviewer.
STATISTICAL ANALYSIS
Descriptive statistics for age, weight, height, trimester (weeks gestation), symptoms at presentation (pain, tenderness, duration of symptoms), clinical conditions (recent surgery, recent hospitalization, cancer, congestive heart failure, recent immobilization, cellulitis, superficial phlebitis and family history of thromboembolic disease) and the LeFT variables (including leg circumference) will be calculated to characterize the study population.
The event rate of thromboembolic complications and death from thromboembolic disease will be calculated for patients with negative whole-leg CUS; both per-protocol and by intention-to-treat.
The rate of isolated iliac DVT detected after vascular technologist suspicion will be reported as a separate calculation with corresponding exct 95% confidence interval
A two-sided confidence interval for the event rate (objectively verified venous thromboembolism) will be calculated for the observation cohort by exact methods. If this confidence interval excludes the commonly accepted threshold event rate of 3%, we will conclude that the diagnostic strategy is clinically valid.
We will also describe the clinical characteristics of clots (e.g. venous distribution) and other endpoints when those data are available.
The sample size of 268 patients who meet eligibility criteria was chosen so that an exact 95% confidence interval would exclude an event rate of venous thromboembolism in the observation cohort of 3%. Excluding an event rate of 3% is the commonly accepted standard by which diagnostic strategies are deemed clinically acceptable.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Deep Vein Thrombosis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
DIAGNOSTIC
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ultrasound for suspected DVT
Enrolled subjects suspected to have deep vein thrombosis undergo whole-leg compression ultrasound. Those with a normal result undergo clinical follow-up for thrombotic outcomes over the following three months.
Group Type
OTHER
Whole-leg compression ultrasound
Intervention Type
OTHER
Duplex ultrasound assessment of the venous system of the leg(s) suspected of deep vein thrombosis. Assessment occurs from the most proximal assessable portion of the common femoral vein (usually at the inguinal ligament) to the level of the malleolus.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Whole-leg compression ultrasound
Duplex ultrasound assessment of the venous system of the leg(s) suspected of deep vein thrombosis. Assessment occurs from the most proximal assessable portion of the common femoral vein (usually at the inguinal ligament) to the level of the malleolus.
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be suspected by the referring medical provider to have a first episode of acute DVT of the lower extremities.
* Be presenting for the initial diagnostic ultrasound for the present symptom complex.
* Pregnancy confirmed by an objective test.
* Be \> 18 years old.
* Provide written informed consent.
* Be presenting for the initial diagnostic ultrasound for the present symptom complex.
* Pregnancy confirmed by an objective test.
* Be \> 18 years old.
* Provide written informed consent.
Exclusion Criteria
* Compression ultrasonography cannot be performed due to physical or technical reasons.
* The patient has a prior history of DVT in the ipsilateral leg.
* Previous venous ultrasound has been performed during the same pregnancy.
* The patient is suspected by the referring clinician to have symptomatic pulmonary embolism.
* Long-term follow-up will not be possible due to geographic inaccessibility, homelessness or lack of a telephone.
* Therapeutic doses of an anticoagulant have been received for more than 24 hours before enrollment.
* Long term anticoagulation will be required for another diagnosis (e.g. atrial fibrillation).
* Informed consent cannot be obtained.
* The patient has a prior history of DVT in the ipsilateral leg.
* Previous venous ultrasound has been performed during the same pregnancy.
* The patient is suspected by the referring clinician to have symptomatic pulmonary embolism.
* Long-term follow-up will not be possible due to geographic inaccessibility, homelessness or lack of a telephone.
* Therapeutic doses of an anticoagulant have been received for more than 24 hours before enrollment.
* Long term anticoagulation will be required for another diagnosis (e.g. atrial fibrillation).
* Informed consent cannot be obtained.
Minimum Eligible Age
18 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Intermountain Health Care, Inc.
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Scott M. Stevens
Transitional Year Program Director
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Scott M Stevens, MD
Role: PRINCIPAL_INVESTIGATOR
Intermountain Health Care, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Intermoutain Medical Center
Murray, Utah, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Wells PS, Anderson DR. Modern approach to diagnosis in patients with suspected deep vein thrombosis. Haemostasis. 1999 Dec;29 Suppl S1:10-20. doi: 10.1159/000054107.
Reference Type
BACKGROUND
Chan WS, Lee A, Spencer FA, Crowther M, Rodger M, Ramsay T, Ginsberg JS. Predicting deep venous thrombosis in pregnancy: out in "LEFt" field? Ann Intern Med. 2009 Jul 21;151(2):85-92. doi: 10.7326/0003-4819-151-2-200907210-00004.
Reference Type
BACKGROUND
Stevens SM, Elliott CG, Chan KJ, Egger MJ, Ahmed KM. Withholding anticoagulation after a negative result on duplex ultrasonography for suspected symptomatic deep venous thrombosis. Ann Intern Med. 2004 Jun 15;140(12):985-91. doi: 10.7326/0003-4819-140-12-200406150-00007.
Reference Type
BACKGROUND
Johnson SA, Stevens SM, Woller SC, Lake E, Donadini M, Cheng J, Labarere J, Douketis JD. Risk of deep vein thrombosis following a single negative whole-leg compression ultrasound: a systematic review and meta-analysis. JAMA. 2010 Feb 3;303(5):438-45. doi: 10.1001/jama.2010.43.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
950359
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
The Diagnosis of Occult Deep Vein Thrombosis of the Lower Extremities in Patients Presenting With Hypoxia
NCT01279746
COMPLETED
The Learning Curve of Emergency Physicians Performed Lower-extremity Ultrasonography in the Diagnosis of DVT
NCT04913688
UNKNOWN
Compression Ultrasonography in Non-high Probability of Deep Vein Thrombosis
NCT04917328
RECRUITING
NA
Diagnostic Performance of General Practitioners in Compression UltraSound
NCT05550038
TERMINATED
NA
Ultrasound Elasticity Imaging of Venous Thrombi
NCT00726947
COMPLETED
EARLY_PHASE1
Sonography Outcomes Assessment Program for Lower Extremity Deep Venous Thrombosis
NCT00178789
COMPLETED
The ERASMUS Study: Limited vs Extended US for DVT Diagnosis
NCT00353093
COMPLETED
NA
Risk of Venous Thromboembolism in Critically Ill Patients With Severe COVID-19
NCT04374617
COMPLETED
Doppler Ultrasound Imaging of Plastic Surgery Patients for DVT Detection
NCT02123550
UNKNOWN
Preventing the Development of Venous Insufficiency in Pregnant Women Through Use of Compression Stockings
NCT01793194
COMPLETED
NA
Location of Lower Extremity Deep Vein Thrombosis by Emergency Physicians Using Portable Compression Ultrasonography
NCT02262494
TERMINATED
NA
Natural History of Isolated Calf Vein Thrombosis - A Prospective Cohort Under Ultrasound Surveillance
NCT06683157
RECRUITING
Prediction of the Risk of Placental Vascular Pathology and Venous Thromboembolic Disease
NCT00695942
COMPLETED
Venous Thrombus Investigation With Contrast Enhanced Ultrasound Imaging
NCT00677846
UNKNOWN
A Comparison of the Effects of Neuromuscular Electrical Stimulation and Intermittent Pneumatic Compression on Blood Flow in the Lower Limb
NCT01894997
COMPLETED
NA
Ultrasound-enhanced Thrombolysis Versus Standard Catheter Directed Thrombolysis for Ilio-femoral Deep Vein Thrombosis
NCT01482273
COMPLETED
NA
Exercise Tolerance After Venous Recanalization for Post-thrombotic Syndrome
NCT05794932
COMPLETED
NA
Ancillary Study of the ULTREC Project
NCT05300139
COMPLETED
Primary Upper Limb Deep Vein Thrombosis. Is First Rib Resection Necessary?
NCT03547921
UNKNOWN
Feasibility of an Early Initiated Physiotherapy Intervention Among Patients With Deep Vein Thrombosis.
NCT05761119
RECRUITING
NA
The Role of Angiojet Rheolytic Thrombectomy in The Management of Iliofemoral Deep Venous Thrombosis
NCT06341010
RECRUITING
Post Market Registry Study of the Philips QuickClear Mechanical Thrombectomy System
NCT05928221
ACTIVE_NOT_RECRUITING
A New Technique to Diagnose Acute and Chronic Deep Vein Thrombosis
NCT02809638
COMPLETED
Graduated Elastic compRession for vAricose Veins in PrEgnancy
NCT05122195
UNKNOWN
Outcome of Percutaneous Mechanical Thrombectomy to Treat Acute Deep Venous Thrombosis
NCT02959801
UNKNOWN
PHASE4